Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy

Abstract Background There is currently no clinical trial data regarding the efficacy of everolimus exemestane (EE) following prior treatment with CDK4/6 inhibitors (CDK4/6i). This study assesses the use and efficacy of everolimus exemestane in patients with metastatic HR+ HER2− breast cancer previou...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Mariya Rozenblit, Sophia Mun, Pamela Soulos, Kerin Adelson, Lajos Pusztai, Sarah Mougalian
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2021-01-01
Schriftenreihe:	Breast Cancer Research
Schlagworte:	Everolimus Exemestane CDK4/6 inhibitors Metastatic hormone-positive HER2-negative breast cancer Sequence of therapy Endocrine therapy
Online-Zugang:	https://doi.org/10.1186/s13058-021-01394-y
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!